|
|
Article: Interim Study Data Demonstrate Eligen[R] B12 Oral Formulation Achieves Comparable Results to B12 Injection - Needleless Option One Step Closer for Millions of Patients with B12 Deficiency.(Clinical report)
- Article from:
- Clinical Trials Week
- Article date:
- November 16, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Emisphere Technologies, Inc. (OTC BB:EMIS) announced that interim data from an ongoing study demonstrated its high-dose oral Eligen[R] B12 (1000mcg) performed as well as or better than B12 injections in individuals with Vitamin B12 deficiency. Normal levels of serum B12 and active B12 were achieved by 100 percent of those study participants who have currently taken Eligen[R] B12 (1000mcg) 15 days into the 90-day study when the first blood samples were taken (see also Life Sciences).
As part of an interim analysis in this randomized, multi-center study, levels of serum B12, active B12, homocysteine and methyl malonic acid were measured on day 15, at which point a ...